These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24119613)

  • 41. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factor VIII assay mimicking in vivo coagulation conditions.
    Kusch M; Grundmann C; Keitel S; König H
    Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a Rapid and Fully Automated Factor VIII-Inhibitor Assay, Insensitive for Emicizumab, and a Lowest Level of Quantification of 0.2BU/mL.
    Verbruggen B; Binder NB; van Velp PJC; Polenewen R; Knöbl P; Sobas F; Moore GW
    J Thromb Haemost; 2024 Jul; ():. PubMed ID: 38992344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A.
    Lindgren A; Wadenvik H; Tengborn L
    Haemophilia; 2002 Sep; 8(5):644-8. PubMed ID: 12199673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Notes on laboratory coagulation testing for acquired hemophilia A].
    Amano K
    Rinsho Byori; 2009 Oct; 57(10):999-1003. PubMed ID: 19928498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alloantibodies to factor VIII in haemophilia.
    Zakarija A; Harris S; Rademaker AW; Brewer J; Krudysz-Amblo J; Butenas S; Mann KG; Green D
    Haemophilia; 2011 Jul; 17(4):636-40. PubMed ID: 21299745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.
    Müller J; Neimanis S; Kahle J; Albert T; Schultze Strasser S; Rup B; Pötzsch B; Königs C; Oldenburg J;
    Haemophilia; 2024 Jan; 30(1):224-231. PubMed ID: 37824540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay.
    Ketteler C; Hoffmann I; Davidson S; Chen D; Tiede A; Richter N
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12799. PubMed ID: 36518189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
    Miller CH; Platt SJ; Rice AS; Kelly F; Soucie JM;
    J Thromb Haemost; 2012 Jun; 10(6):1055-61. PubMed ID: 22435927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
    Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
    Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B; Novakova I; Wessels H; Boezeman J; van den Berg M; Mauser-Bunschoten E
    Thromb Haemost; 1995 Feb; 73(2):247-51. PubMed ID: 7792738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A.
    Wang XF; Zhao YQ; Yang RC; Wu JS; Sun J; Zhang XS; Ding QL; Ge HL; Wang HL
    Haemophilia; 2010 Jul; 16(4):632-9. PubMed ID: 20331753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.